MC4R and obesity due to melanocortin 4 receptor deficiency: It is worth noting that one MC4R agonist (Setmelanotide) has been approved for use in patients with obesity, but it can only be prescribed to patients who are confirmed to have obesity-causing gene mutations in the melanocortin pathway instead of general obesity37.